InsideTrading SEC Form 4 insider trades

Stocks

KROS Keros Therapeutics, Inc.

Healthcare · Market cap: $204.2M

–

Bought and sold by quarter, last 5 years

Open-market purchases and sales by this company's insiders, in dollars, last 5 years

Quarterly insider purchases and sales 2022-Q1: bought $0, sold $3.3M 2022-Q2: bought $0, sold $1.2M 2022-Q3: bought $0, sold $1.4M 2022-Q4: bought $0, sold $0 2023-Q1: bought $0, sold $0 2023-Q2: bought $0, sold $1.9M 2023-Q3: bought $0, sold $0 2023-Q4: bought $0, sold $1.8M 2024-Q1: bought $0, sold $1.8M 2024-Q2: bought $0, sold $0 2024-Q3: bought $0, sold $22.0M 2024-Q4: bought $0, sold $0 2025-Q1: bought $0, sold $0 2025-Q2: bought $9.5M, sold $0 2025-Q3: bought $0, sold $0 2025-Q4: bought $0, sold $180.6M 2026-Q1: bought $22.4K, sold $331.8K 2026-Q2: bought $32.5K, sold $90.0K 2026-Q3: bought $20.9K, sold $101.1K 2026-Q4: bought $0, sold $0
Bought, above the line (largest quarter $9.5M) Plan or routine purchases (part of bought) Sold, below the line (largest quarter $180.6M)
Quarterly insider purchases and sales
QuarterBoughtSold
2022-Q1$0$3.3M
2022-Q2$0$1.2M
2022-Q3$0$1.4M
2022-Q4$0$0
2023-Q1$0$0
2023-Q2$0$1.9M
2023-Q3$0$0
2023-Q4$0$1.8M
2024-Q1$0$1.8M
2024-Q2$0$0
2024-Q3$0$22.0M
2024-Q4$0$0
2025-Q1$0$0
2025-Q2$9.5M$0
2025-Q3$0$0
2025-Q4$0$180.6M
2026-Q1$22.4K$331.8K
2026-Q2$32.5K$90.0K
2026-Q3$20.9K$101.1K
2026-Q4$0$0

Insider activity

Download CSV Up to 5,000 rows
Bought$9.5M7 buy days
Sold$217.3M38 sell days
Net insider flow-$207.8Mnet selling · 5 years
Latest trade2026-08-18Cho Esther
Insider trades for this stock
Date Side Insider Role Shares Avg price Value Trades
2026-08-18 Sell Cho Esther Other C-suite 4,485 $10.29 $46.2K 1
2026-08-18 Sell Lerner Lorena Raquel Other C-suite 3,568 $10.29 $36.7K 1
2026-08-18 Sell Tanini Annita VP 1,224 $10.29 $12.6K 1
2026-08-18 Sell Newton Charles W. Director 551 $10.30 $5.7K 1
2026-08-17 Buy BIENAIME JEAN JACQUES Director 1,000 $10.27 $10.3K 1
2026-07-15 Buy BIENAIME JEAN JACQUES Director 1,000 $10.61 $10.6K 1
2026-06-15 Buy BIENAIME JEAN JACQUES Director 1,000 $10.19 $10.2K 1
2026-06-11 Sell Newton Charles W. Director 550 $10.04 $5.5K 1
2026-06-04 Sell Knowles Julius Director 2,625 $10.73 $28.2K 1
2026-06-04 Sell Farzan Nima Director 2,625 $10.73 $28.2K 1
2026-06-04 Sell Seth Alpna Director 2,625 $10.72 $28.1K 1
2026-05-15 Buy BIENAIME JEAN JACQUES Director 1,000 $10.58 $10.6K 1
2026-04-15 Buy BIENAIME JEAN JACQUES Director 1,000 $11.70 $11.7K 1
2026-03-09 Buy BIENAIME JEAN JACQUES Director 2,000 $11.21 $22.4K 1
2026-02-19 Sell Seehra Jasbir CEO 7,015 $16.17 $113.4K 1
2026-02-18 Sell Cho Esther General counsel 4,745 $16.35 $77.6K 1
2026-02-18 Sell Regnante Keith CFO 4,739 $16.35 $77.5K 1
2026-02-18 Sell Lerner Lorena Raquel Other C-suite 3,873 $16.35 $63.3K 1
2025-10-15 Sell ADAR1 Partners, LP 10% owner 5,389,264 $17.75 $95.7M 3
2025-10-15 Sell Kariv Tomer Director 4,787,331 $17.75 $85.0M 4
2025-04-09 Buy ADAR1 Partners, LP 10% owner 934,258 $10.13 $9.5M 5
2024-08-13 Sell GORDON CARL L Director 250,000 $44.01 $11.0M 2
2024-08-13 Sell ORBIMED ADVISORS LLC Director 250,000 $44.01 $11.0M 2
2024-01-04 Sell Regnante Keith CFO 40,000 $45.29 $1.8M 1
2023-11-04 Sell Regnante Keith CFO 40,000 $45.29 $1.8M 1
2023-06-09 Sell Regnante Keith CFO 20,000 $45.42 $908.4K 3
2023-06-08 Sell Regnante Keith CFO 20,000 $47.79 $955.9K 2
2022-07-15 Sell Lachey Jennifer Other C-suite 46,034 $30.00 $1.4M 1
2022-07-13 Sell Lachey Jennifer Other C-suite 1,916 $30.00 $57.5K 1
2022-05-11 Sell Lachey Jennifer Other C-suite 5,300 $41.90 $222.0K 5
2022-04-11 Sell Lachey Jennifer Other C-suite 5,300 $62.77 $332.7K 4
2022-04-06 Sell Rovaldi Christopher COO 1,728 $65.00 $112.3K 1
2022-04-04 Sell Lachey Jennifer Other C-suite 7,950 $60.00 $477.0K 1
2022-04-01 Sell Rovaldi Christopher COO 864 $57.49 $49.7K 5
2022-03-11 Sell Lachey Jennifer Other C-suite 2,650 $53.38 $141.4K 3
2022-02-11 Sell Lachey Jennifer Other C-suite 2,650 $52.06 $138.0K 3
2022-01-11 Sell Lachey Jennifer Other C-suite 2,650 $53.75 $142.4K 3
2022-01-05 Sell Knowles Julius Director 4,034 $58.25 $235.0K 6
2022-01-05 Sell Lachey Jennifer Other C-suite 2,650 $60.00 $159.0K 1
2022-01-04 Sell Knowles Julius Director 20,062 $57.55 $1.2M 10
2022-01-03 Sell Knowles Julius Director 23,555 $58.01 $1.4M 8
2021-12-15 Sell Lachey Jennifer Other C-suite 735 $50.00 $36.8K 1
2021-12-13 Sell Lachey Jennifer Other C-suite 1,915 $50.55 $96.8K 3
2021-12-02 Sell Knowles Julius Director 25,338 $53.57 $1.4M 8
2021-12-01 Sell Knowles Julius Director 22,313 $54.68 $1.2M 8

Who the insiders are, last 5 years

Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.

Insiders of this company with their purchases and sales
Insider Role Bought Sold Last trade
ADAR1 Partners, LP 10% owner $9.5M $95.7M 2025-10-15
Kariv Tomer Director $0 $85.0M 2025-10-15
GORDON CARL L Director $0 $11.0M 2024-08-13
ORBIMED ADVISORS LLC Director $0 $11.0M 2024-08-13
Regnante Keith CFO $0 $5.6M 2026-02-18
Knowles Julius Director $0 $5.4M 2026-06-04
Lachey Jennifer Other C-suite $0 $3.2M 2022-07-15
Rovaldi Christopher COO $0 $162.0K 2022-04-06
Cho Esther Other C-suite $0 $123.7K 2026-08-18
Seehra Jasbir CEO $0 $113.4K 2026-02-19
Lerner Lorena Raquel Other C-suite $0 $100.0K 2026-08-18
BIENAIME JEAN JACQUES Director $75.8K $0 2026-08-17
Farzan Nima Director $0 $28.2K 2026-06-04
Seth Alpna Director $0 $28.1K 2026-06-04
Tanini Annita VP $0 $12.6K 2026-08-18
Newton Charles W. Director $0 $11.2K 2026-08-18

Past buying clusters

A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.

Buying clusters at this company, newest first, with the return against the benchmark that followed
Window Insiders Total Score 21 days vs benchmark63 days vs benchmark126 days vs benchmark Status
2020-04-13 7 $23.2M 62 +21.2% (+21.4% raw)+17.8% (+31.8% raw)+80.0% (+106.5% raw) closed

Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.